Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860588 | 0.94 | MEN1 (0.51) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3861517 | 0.94 | MEN1 (0.51) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3854103 | 0.87 | MEN1 (0.61) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3858124 | 0.86 | MEN1 (0.52) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3851646 | 0.85 | MEN1 (0.59) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3852090 | 0.85 | MEN1 (0.51) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3857230 | 0.84 | MEN1 (0.55) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL21726067 | 0.84 | MEN1 (0.57) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3856237 | 0.84 | MEN1 (0.57) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3856269 | 0.84 | MEN1 (0.52) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044457-A1 | Pharmaceutical Composition Comprising Temozolomide Ester | TIAN JIN KINSLY PHARMACEUTICAL R&D CO. LTD. (CN) | 2008-02-21 | — | — | US | claimed |
| EP-1798234-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TEMOZOLOMIDE ESTER | Tianjin Tasly Group Co., Ltd. (CN) | 2007-06-20 | — | — | EP | claimed |
| EP-1798234-B1 | PHARMACEUTICAL COMPOSITION COMPRISING TEMOZOLOMIDE ESTER | TIANJIN TASLY GROUP CO LTD (CN) | 2012-06-13 | — | — | EP | disclosed |
| US-7579336-B2 | Pharmaceutical composition comprising temozolomide ester | TIAN JIN TASLY GROUP CO., LTD. (CN) | 2009-08-25 | — | — | US | disclosed |
| US-20080044457-A1 | Pharmaceutical Composition Comprising Temozolomide Ester | TIAN JIN KINSLY PHARMACEUTICAL R&D CO. LTD. (CN) | 2008-02-21 | — | — | US | disclosed |
| EP-1798234-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TEMOZOLOMIDE ESTER | Tianjin Tasly Group Co., Ltd. (CN) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044457-A1 | Pharmaceutical Composition Comprising Temozolomide Ester | MGMT, TET1, CYP2C8 | MEN1 211/4885PABPC1 3682/4885KMT2A 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.